Global medical technology company Anteo Diagnostics has successfully completed the first milestone in their Defence Materials Technology Centre (DMTC) medical countermeasures project.
Anteo united with Planet Innovation, Deakin University and DMTC for a partnership study as part of DMTC's Medical Countermeasures (MCM) program.
The partnership focuses on furthering the technology readiness of Nplex, Planet Innovation’s low cost, high sensitivity point of care diagnostic system using breakthrough reader technology.
The Nplex technology is ideally suited for applications where high sensitivity, multiplexed assay systems are needed for the rapid identification of infectious agents, especially in remote locations.
Nplex technology has the potential to be used to protect Australian military and civilian personnel against chemical, biological and radiological threats, emerging infectious diseases and pandemics.
Anteo’s contribution and objectives in 'Milestone 1' were to successfully functionalise nanoparticles requiring integration with Planet Innovation’s reader. Anteo has successfully established, optimised and verified a model lateral flow system for the nominated target assay using Mix&Go.
Work on the next milestone is already underway and is scheduled to be completed by next quarter.
Milestone 2 is focused on building further robustness and reproducibility of its conjugates while progressively driving for maximum achievable assay sensitivity.
Anteo Technologies head of R&D Charlie Huang said Anteo expects their contribution tot he project will meet and exceed set targets.
"Anteo expects to provide the partnership with a robust technical and commercial solution that can be applied to many different assays and not just the target assay currently being investigated," said Huang.
Subscribe to the Defence Connect daily newsletter.
Be the first to hear the latest developments in the defence industry.
Planet Innovation expects the same, with the company's general manager - Nplex Dr Sacha Dopheide saying the performance so far is exceeding expectations.
"First pass optimisation indicates that Anteo’s conjugate and assay chemistry is performing above expectations with a respectable signal to noise ratio," said Dopheide. "We are encouraged by the results on Milestone 1 and look forward to seeing where Anteo can take their technology in this project."